Inhibition Of Protein Tyrosine Phosphatase - Sigma For Hematopoietic Regeneration
15 fold increase in hematologic recoveryApplicable for both white and red blood cell regenerationExtensively characterized mechanism of action
Treatment of patients undergoing hematopoietic cell transplantationTreatment of myelosuppressive chemotherapyTreatment of anemia caused by chronic kidney disease in patients on dialysis
UCLA researchers in the Departments of Medicine and Chemistry and Biochemistry have identified a novel receptor, Protein tyrosine phosphatase sigma (PTPS) expressed on hematopoitic stem cells. They have characterized the mechanism extensively in vivo by knockout studies and found that PTPS regulates HSC regeneration. Based on their discovery, they have developed novel inhibitors targeting PTPS that cause dramatic hematopoitic stem cell regeneration in mice models and significantly improve the life span in mice receiving fatal irradiation.
State Of Development Background Depletion of white and red blood cells also known as Myelosuppression is a common side effect of chemotherapy and radiotherapy. Currently, one FDA approved growth factor is used that increases white blood cell count but there are no therapies for total blood cell regeneration. Hematopoietic stem cells (HSCs) offer an alternative therapy, as they are a reservoir of both white and red blood cells. However, the mechanistic details of factors that govern HSC regeneration and proliferation are not known and no therapeutics that can increase HSC regeneration are available. Related Materials Additional Technologies by these Inventors Tech ID/UC Case 27473/2016-518-0 Related Cases 2016-518-0
美國
